Recombinant Dna Biosciences Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 8 Year, 1 Month
- Last Filing with ROC 31 Mar 2023
- Revenue Growth -2.97%
- Profit Growth -26.49%
- Ebitda -21.16%
- Net Worth 22.86%
- Total Assets 21.98%
About Recombinant Dna Biosciences
Recombinant Dna Biosciences Private Limited (RDBPL) is a registered startup operating as a Private Limited Indian Non-Government Company incorporated in India on 20 December 2016 (Eight years and one month 11 days old ). Its registered office is in West Delhi, Delhi, India.
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Raju Jaiswal, Piyoosh Mishra, Kaushlesh Singh, and One other member serve as directors at the Company.
Company Details
-
Location
West Delhi, Delhi, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U74999DL2016PTC309441
-
Company No.
309441
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
20 Dec 2016
-
Date of AGM
30 Sep 2023
-
Date of Balance Sheet
31 Mar 2023
-
Listing Status
Unlisted
-
ROC Code
Roc Delhi
Industry
Who are the key members and board of directors at Recombinant Dna Biosciences?
Board Members (4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Kaushlesh Singh
|
Additional Director | 16-Feb-2024 | Current |
|
Chandra Maheshwari
|
Director | 26-Jan-2019 | Current |
|
Raju Jaiswal
|
Director | 13-Oct-2017 | Current |
|
Piyoosh Mishra
|
Director | 13-Oct-2017 | Current |
Financial Performance of Recombinant Dna Biosciences.
Recombinant Dna Biosciences Private Limited, for the financial year ended 2023, experienced Minor drop in revenue, with a 2.97% decrease. The company also saw a substantial fall in profitability, with a 26.49% decrease in profit. The company's net worth Soared by an impressive increase of 22.86%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Recombinant Dna Biosciences?
In 2022, Recombinant Dna Biosciences had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Recombinant Dna Biosciences?
Unlock and access historical data on people associated with Recombinant Dna Biosciences, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Recombinant Dna Biosciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Recombinant Dna Biosciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
